Literature DB >> 31686421

Cognitive and psychiatric symptoms in genetically determined Parkinson's disease: a systematic review.

R Piredda1,2, P Desmarais3,4,5,6, M Masellis3,4,5,6,7, C Gasca-Salas1,8.   

Abstract

The aim was to review the existing reports on cognitive and behavioural symptoms in monogenic forms of Parkinson's disease (PD) and to identify recurring patterns of clinical manifestations in those with specific mutations. A systematic literature search was conducted to retrieve observational studies of monogenic PD. Data pertaining to cognitive and psychiatric manifestations were extracted using standardized templates. The PRISMA guidelines were followed. Of the 1889 citations retrieved, 95 studies on PD-related gene mutations were included: 35 in SNCA, 35 in LRRK2, four in VPS35, 10 in Parkin, three in DJ1 and eight in PINK1. Nineteen studies (20%) provided adequate data from comprehensive cognitive assessment and 31 studies (32.6%) outlined psychiatric manifestations through the use of neuropsychiatric scales. Cognitive impairment was reported in all monogenic PD forms with variable rates (58.8% PINK1, 53.9% SNCA, 50% DJ1, 29.2% VPS35, 15.7% LRRK2 and 7.4% Parkin). In this regard, executive functions and attention were the domains most affected. With respect to psychiatric symptoms, depression was the most frequent symptom, occurring in 37.5% of PINK1 cases and 41.7% of VPS35 and LRRK2 cases. Co-occurrence of cognitive decline with visual hallucinations was evidenced. Widespread accumulation of Lewy bodies, distinctive of SNCA, PINK1 and DJ1 mutations, results in higher rates of cognitive impairment. Similarly, a higher degree of visual hallucinations is observed in SNCA mutations, probably owing to the more widespread accumulation. The lower rates of α-synuclein pathology in LRRK2 and Parkin may underpin the more benign disease course in these patients.
© 2019 European Academy of Neurology.

Entities:  

Keywords:  zzm321990DJ1zzm321990; zzm321990LRRK2zzm321990; zzm321990PINK1zzm321990; zzm321990Parkinzzm321990; zzm321990SNCAzzm321990; zzm321990VPS35zzm321990; behavioural symptoms; dementia; monogenic Parkinson's disease

Year:  2019        PMID: 31686421     DOI: 10.1111/ene.14115

Source DB:  PubMed          Journal:  Eur J Neurol        ISSN: 1351-5101            Impact factor:   6.089


  15 in total

Review 1.  Na+ leak-current channel (NALCN) at the junction of motor and neuropsychiatric symptoms in Parkinson's disease.

Authors:  Merve Kasap; Donard S Dwyer
Journal:  J Neural Transm (Vienna)       Date:  2021-05-07       Impact factor: 3.575

2.  Cognitive deficits and altered cholinergic innervation in young adult male mice carrying a Parkinson's disease Lrrk2G2019S knockin mutation.

Authors:  Ayan Hussein; Alexander Tielemans; Mark G Baxter; Deanna L Benson; George W Huntley
Journal:  Exp Neurol       Date:  2022-06-19       Impact factor: 5.620

Review 3.  Depression in Patients with Parkinson's Disease: Current Understanding of its Neurobiology and Implications for Treatment.

Authors:  Stéphane Prange; Hélène Klinger; Chloé Laurencin; Teodor Danaila; Stéphane Thobois
Journal:  Drugs Aging       Date:  2022-06-16       Impact factor: 4.271

Review 4.  Mitophagy in depression: Pathophysiology and treatment targets.

Authors:  Ashutosh Tripathi; Giselli Scaini; Tatiana Barichello; João Quevedo; Anilkumar Pillai
Journal:  Mitochondrion       Date:  2021-08-31       Impact factor: 4.160

5.  Non-Motor Symptoms of Parkinson's Disease: The Neurobiology of Early Psychiatric and Cognitive Dysfunction.

Authors:  Ayan Hussein; Christopher A Guevara; Pamela Del Valle; Swati Gupta; Deanna L Benson; George W Huntley
Journal:  Neuroscientist       Date:  2021-05-08       Impact factor: 7.235

6.  LRRK2 p.M1646T is associated with glucocerebrosidase activity and with Parkinson's disease.

Authors:  Yuri L Sosero; Eric Yu; Lynne Krohn; Uladzislau Rudakou; Kheireddin Mufti; Jennifer A Ruskey; Farnaz Asayesh; Sandra B Laurent; Dan Spiegelman; Stanley Fahn; Cheryl Waters; S Pablo Sardi; Sara Bandres-Ciga; Roy N Alcalay; Ziv Gan-Or; Konstantin Senkevich
Journal:  Neurobiol Aging       Date:  2021-02-28       Impact factor: 5.133

Review 7.  Disruption of Mitochondrial Homeostasis: The Role of PINK1 in Parkinson's Disease.

Authors:  Maria Vizziello; Linda Borellini; Giulia Franco; Gianluca Ardolino
Journal:  Cells       Date:  2021-11-04       Impact factor: 6.600

Review 8.  Neuronal autophagy and mitophagy in Parkinson's disease.

Authors:  Britney N Lizama; Charleen T Chu
Journal:  Mol Aspects Med       Date:  2021-06-12

Review 9.  Cognitive Impairment in Parkinson's Disease: Epidemiology, Clinical Profile, Protective and Risk Factors.

Authors:  Paulina Gonzalez-Latapi; Ece Bayram; Irene Litvan; Connie Marras
Journal:  Behav Sci (Basel)       Date:  2021-05-13

Review 10.  Profiling Non-motor Symptoms in Monogenic Parkinson's Disease.

Authors:  Xinyao Liu; Weidong Le
Journal:  Front Aging Neurosci       Date:  2020-10-30       Impact factor: 5.750

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.